The purpose of this study in healthy volunteers is to assess the relative bioavailability of PF-05175157 as powder-in-capsule and a tablet formulation and the effect of food on the pharmacokinetics of the tablet formulation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
12
Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)
Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
Pfizer Investigational Site
New Haven, Connecticut, United States
Maximum Observed Plasma Concentration (Cmax)
Time frame: 0 to 72 H after dose
Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf)
Time frame: 0 to 72 H after dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Time frame: 0 to 72 H after dose
Time at which maximum plasma concentration is observed (Tmax)
Time frame: 0 to 72 H after dose
Plasma Decay Half-Life (t1/2)
Time frame: 0 to 72 H after dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)